Portage Biotech Corp (PRTG): שווי מצרפי של הפעילות העסקית

Portage Biotech Inc. (PRTG) minimizes operational risks by distributing early-stage testing across various contract research organizations. The issuer's revenues are based on partner payments for AI-driven inhibitor discovery and the future sale of immune-stimulating agents. The historical Enterprise Value price action, reaching , confirms the platform's potential to create high-precision and less toxic methods for combating tumors.

The investor determines the asset's margin of safety through the sum of market capitalization and net debt, which allows for the filtering of speculative noise from the business's intrinsic value. The current Enterprise Value assessment reflects the acquisition costs of Portage Biotech Inc. (PRTG) considering its expansion into the oncology sector and the scaling of its iNKT pipeline, characterizing this biopharmaceutical asset as a high-risk instrument with market capture potential.